Tengion, Inc.  

(Public, OTCMKTS:TNGN)   Watch this stock  
Find more results for TNGN
-0.005 (-2.50%)
Apr 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.18 - 0.20
52 week 0.15 - 1.39
Open 0.20
Vol / Avg. 174,568.00/485,235.00
Mkt cap 3.56M
P/E     -
Div/yield     -
EPS -6.35
Shares 18.23M
Beta 2.58
Inst. own 17%
May 12, 2014
Q1 2014 Tengion, Inc. Earnings Release (Estimated) Add to calendar
Mar 26, 2014
Q4 2013 Tengion, Inc. Earnings Release
Mar 10, 2014
Tengion, Inc. at ROTH Conference - Webcast

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 84.10% -99.20%
Return on average equity - -
Employees 25 -
CDP Score - -


Suite G, 3929 Westpoint Blvd.
United States - Map
+1-336-7225855 (Phone)
+1-302-6555049 (Fax)

Website links


Tengion, Inc. (Tengion) is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues. The Company focuses on creating these functional neo-organs and neo-tissues using a patient�s own cells, or autologous cells, in conjunction with its Organ Regeneration Platform. Tengion manufactures product candidates in its facilities using processes and it has implanted its neo-organs in clinical trials. The Company focuses on developing its technology to address medical needs in urologic, renal, gastrointestinal and vascular diseases.

Officers and directors

David I. Scheer Independent Chairman of the Board
Age: 60
Timothy A Bertram Ph.D. President - Research and Development, Chief Scientific Officer
Age: 57
John L. Miclot President, Chief Executive Officer, Director
Age: 54
A Brian Davis Chief Financial Officer, Senior Vice President - Finance
Age: 46
Carl-Johan Dalsgaard M.D. Independent Director
Age: 55
Diane K. Jorkasky M.D. Independent Director
Age: 60
Richard E. Kuntz M.D. Independent Director
Age: 56
Lorin Jeffry Randall Independent Director
Age: 69